公开(公告)号：EP2477030A2

公开(公告)日：2012-07-18

申请号：EP10763733.2

申请日：2010-09-07

申请人： Fundación del Hospital Nacional de Parapléjicos Para la Investigación y la Integración

发明人： DE CASTRO SOUBRIET, Fernando ,  CLEMENTE LÓPEZ, Diego ,  ORTEGA MUÑOZ, María Cristina ,  ARENZANA SANAGÉRICO, Francisco Javier

IPC分类号： G01N33/68

CPC分类号： G01N33/6896 ,  G01N2333/50 ,  G01N2800/285 ,  G01N2800/50

摘要： Use of the FGF-2 and anosmin-1 proteins for predicting the histopathology of the lesions of a patient suffering from a central nervous system (CNS) demyelinating disease by means of the detection of the amount of said proteins in a sample of isolated biological fluid. Furthermore, the present invention relates to a method for ascertaining the histopathological characteristics of the lesions of a patient suffering from a CNS demyelinating disease and to a kit for implementing said method. Preferably, the CNS demyelinating disease is multiple sclerosis and the biological fluid is cerebrospinal fluid (CSF)..

摘要翻译： 使用FGF-2和anosmin-1蛋白质通过检测分离的生物流体样品中所述蛋白质的量来预测患有中枢神经系统（CNS）脱髓鞘病患者的病变的组织病理学 。 此外，本发明涉及确定患有CNS脱髓鞘疾病的患者的病变的组织病理学特征的方法以及用于实施所述方法的试剂盒。 优选地，CNS脱髓鞘病是多发性硬化，生物流体是脑脊髓液（CSF）。

公开(公告)号：EP2440931A2

公开(公告)日：2012-04-18

申请号：EP10721033.8

申请日：2010-06-08

申请人： Fundació Privada Institut D'investigació Biomèdica De Bellvitge (IDIBELL) ,  Universitat Pompeu-Fabra ,  Universitat de Barcelona ,  Institut Català D'Oncologia

发明人： SANZ PAMPLONA, Rebeca ,  SIERRA JIMENEZ, Angels ,  OLIVA MIGUEL, Baldomero ,  MORENO AGUADO, Victor Raul ,  GIL GIL, Juan Miguel

IPC分类号： G01N33/574

CPC分类号： G01N33/57407 ,  G01N33/57415 ,  G01N2333/50

摘要： The method comprises: (a) isolating a sample from the breast tumour; (b) determining the level of expression of GRP94, FN14 or both in the sample, and (c) comparing said level with the level of said gene(s) in a control sample, wherein if it is detected an overexpression of said gene(s), in respect of the control sample, it is indicative of the risk for developing brain metastasis. The kit to carry out the method of the invention comprises appropriate means to determine the level of expression of each one of the markers. Both, the method and kit provides accurate information about the risk of developing brain metastasis in an early state, which can lead to a reduction of the incidence of breast cancer brain metastasis.

公开(公告)号：EP2393934A1

公开(公告)日：2011-12-14

申请号：EP10739152.6

申请日：2010-02-05

申请人： Astute Medical, Inc.

发明人： ANDERBERG, Joseph ,  GRAY, Jeff ,  MCPHERSON, Paul ,  NAKAMURA, Kevin

IPC分类号： C12Q1/02

CPC分类号： G01N33/6893 ,  G01N2333/50 ,  G01N2800/347 ,  G01N2800/56

摘要： The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of soluble Advanced glycosylation end product- specific receptor, Bactericidal permeability-increasing protein, Interleukin 12, Fibroblast growth factor 23, Vitamin K-dependent protein C, and Intestinal fatty acid-binding protein as diagnostic and prognostic biomarkers in renal injuries.

公开(公告)号：EP1718756B1

公开(公告)日：2011-11-16

申请号：EP05724048.3

申请日：2005-02-23

申请人： ALLERGAN, INC.

发明人： FERNANDEZ-SALAS, Ester ,  GARY, Patton, E. ,  AOKI, Kei, Roger

IPC分类号： C12Q1/00

CPC分类号： G01N33/56911 ,  G01N2333/50

摘要： Methods for detecting BoNT/A activity in a sample, methods for screening molecules able to compete with BoNT/A receptor binding, methods for reducing BoNT/A activity in a human and methods of marketing a neurotoxin capable of selectively binding to FGFR3 to a governmental or regional regulatory authority.

公开(公告)号：EP2284189A2

公开(公告)日：2011-02-16

申请号：EP10010387.8

申请日：2000-09-05

申请人： Amgen, Inc

发明人： Thomason, Arlen ,  Liu, Benxian

IPC分类号： C07K14/50 ,  C12N15/19 ,  A61K38/19 ,  A61K38/48

CPC分类号： C07K14/50 ,  A61K38/00 ,  C07K2319/30 ,  C12N2310/111 ,  G01N2333/50

摘要： The present invention provides nucleic acid molecules encoding Fibroblast Growth Factor-like (FGF-like) polypeptides. The invention also provides vectors, host cells, and methods for producing FGF-like polypeptides. Also provided for are methods for the diagnosis and treatment of diseases associated with FGF-like polypeptides

摘要翻译： 本发明提供了编码成纤维细胞生长因子样（FGF样）多肽的核酸分子。 本发明还提供了用于生产FGF样多肽的载体，宿主细胞和方法。 还提供了诊断和治疗与FGF样多肽相关的疾病的方法

公开(公告)号：EP2189475A2

公开(公告)日：2010-05-26

申请号：EP09002072.8

申请日：2000-09-05

申请人： Amgen Inc.

发明人： Thomason, Arlen ,  Liu, Benxian

IPC分类号： C07K14/50 ,  C12N15/19

CPC分类号： C07K14/50 ,  A61K38/00 ,  C07K2319/30 ,  C12N2310/111 ,  G01N2333/50

摘要： The present invention provides Fibroblast Growth Factor-like (FGF-like) polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, antibodies and methods for producing FGF-like polypeptides. Also provided for are methods for the diagnosis and treatment of diseases associated with FGF-like polypeptides.

摘要翻译： 本发明提供了成纤维细胞生长因子样（FGF样）多肽和编码其的核酸分子。 本发明还提供了用于产生FGF样多肽的载体，宿主细胞，抗体和方法。 还提供了诊断和治疗与FGF样多肽相关的疾病的方法。

公开(公告)号：EP2139508A2

公开(公告)日：2010-01-06

申请号：EP08826247.2

申请日：2008-04-01

申请人： Genentech, Inc.

发明人： DESNOYERS, Luc

IPC分类号： A61K38/17 ,  G01N33/50 ,  C12Q1/00 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10 ,  A61P9/00 ,  A61P9/12 ,  A61P11/00 ,  A61P35/00 ,  A61P1/16 ,  A61P5/50

CPC分类号： C07K16/40 ,  A61K31/138 ,  A61K31/4196 ,  A61K31/4745 ,  A61K31/475 ,  A61K31/506 ,  A61K31/517 ,  A61K31/565 ,  A61K31/5685 ,  A61K38/17 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K14/71 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/75 ,  C07K2317/76 ,  G01N33/5032 ,  G01N33/57438 ,  G01N33/57492 ,  G01N33/74 ,  G01N2333/50 ,  G01N2333/705 ,  G01N2333/71 ,  G01N2500/02 ,  G01N2500/04 ,  G01N2500/10 ,  A61K2300/00

摘要： The invention concerns uses of anti-KLBeta agents, and detection of KLBeta and/or FGF19 and/or FGFR4.

摘要翻译： 本发明涉及使用抗KLBeta剂，和KLBeta和/或FGF19和/或FGFR4的检测。

公开(公告)号：EP1664075A2

公开(公告)日：2006-06-07

申请号：EP04781657.4

申请日：2004-08-20

申请人： Curagen Corporation

发明人： SHIMKETS, Richard, A.

IPC分类号： C07H21/02 ,  C07H21/04 ,  C07K14/435 ,  C12Q1/68 ,  A61K38/17 ,  A61K39/395 ,  A61K48/00 ,  G01N33/53

CPC分类号： G01N33/6872 ,  A61K38/1825 ,  C12Q1/6883 ,  C12Q2600/156 ,  G01N33/74 ,  G01N2333/50 ,  G01N2800/04 ,  G01N2800/52

摘要： The present invention describes novel methods for diagnosis and treatment of conditions that alter phosphate transport in mammals. The fibroblast growth factor proteins and nucleotides that may be useful as a therapeutic or in the diagnosis of such conditions are also described.

公开(公告)号：EP1579218A2

公开(公告)日：2005-09-28

申请号：EP03779758.6

申请日：2003-12-18

申请人： Enkam Pharmaceuticals A/S

发明人： BEREZIN, Vladimir ,  ALBRECHTSEN, Morten ,  BOCK, Elisabeth

IPC分类号： G01N33/566 ,  C07K7/00

CPC分类号： C07K7/06 ,  A61K38/00 ,  C07K7/08 ,  C07K16/22 ,  G01N33/566 ,  G01N33/74 ,  G01N2333/50

摘要： The present invention relates to a method for modulating the interaction between at least two proteins, wherein at least one of the two proteins is a functional cell-surface receptor and the other protein is the receptor ligand. The invention features a binding site of said functional cell-surface receptor on the receptor ligand and discloses a series of amino acid sequences, which are part of the structure of said binding site and/or involved in the interaction between the receptor and the ligand. Moreover, the present invention features methods for molecular design and screening of a candidate compound capable of modulating the interaction between the functional cell-surface receptor and receptor ligand through the described binding site, and provides a screening assay for identification of such a compound. The invention further describes an antibody capable of binding to the above binding site and/or to an epitope comprising an amino acid sequence essential for executing the receptor ligand interaction through said binding site. The invention also concerns a variety of uses of the disclosed methods, peptide sequences and antibodies. The invention in preferred embodiments concerns the binding site of the fibroblast growth factor receptor (FGFR) on FGFR ligands, compounds capable of modulating the receptor ligand interaction through said binding site, and antibody capable of recognition of said binding site.

公开(公告)号：EP1342476A3

公开(公告)日：2003-09-17

申请号：EP02022340.0

申请日：1996-06-12

申请人： YEDA RESEARCH AND DEVELOPMENT CO. LTD. ,  RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH & INDUSTRIAL DEVELOPMENT LTD.

发明人： Yayon, Avner ,  Nevo, Zvi

IPC分类号： A61K47/48 ,  A61K38/18

CPC分类号： G01N33/566 ,  A61K38/00 ,  A61K2039/505 ,  C07K14/50 ,  C07K16/2863 ,  G01N33/53 ,  G01N33/56966 ,  G01N33/6887 ,  G01N33/74 ,  G01N2333/50 ,  G01N2333/9121

摘要： The present invention concerns fibroblast growth factor receptor 3 (FGFR3) as a novel marker for mesenchymal skeletal progenitor cells. By utilizing this novel marker it was possible both to identify and locate mesenchymal skeletal progenitor cells in a tissue, as well as to obtain a substantially pure culture of such cells. The pure culture of the mesenchymal skeletal progenitor cells may be used, optionally after various manipulations ex vivo , as an active ingredient in pharmaceutical compositions or implants for the purpose of bone and/or cartilage repair. FGFR3 may also be used as a marker for the identification and the localization of cartilage- and bone-derived tumors. Agents capable of binding to FGFR3 may also be used for targeting cytotoxic agents to cartillage- and bone-derived tumors.